Through June 22, 2026, state-licensed medical marijuana licensees have a short window to register with the DEA to handle medical marijuana under the new federal Schedule III framework. To register or not to register? That is the question.
Following the April 23, 2026, federal rescheduling order, DEA is calling on state-licensed medical marijuana cultivators, producers, distributors, transporters, wholesalers and retailers to register with the agency. A timely registration provides a limited “safe harbor,” allowing the operator to continue its state-licensed medical marijuana operation while DEA reviews the application. Failure to timely register may subject the licensee to federal enforcement actions.
That sounds like a meaningful opportunity. It may be. But licensees should not mistake registration for a guaranteed benefit or a simple administrative filing. The clearest benefit is the limited safe harbor while DEA reviews a timely application. Other potential advantages, including tax relief, improved access to capital and greater comfort among banks, insurers and business partners, remain fact-specific and uncertain.
The tax issue will get the most attention, and understandably so. Registration may strengthen the argument that a medical marijuana business can take ordinary business deductions that have long been unavailable under Section 280E. For many licensees, that could be a substantial benefit. But “may” is the operative word here. The actual benefit will depend on the licensee’s business, its medical versus adult-use activity, its tax position, and how federal agencies administer the new framework.
Registration also comes with real burdens. There are ongoing federal and state compliance obligations, product testing, onsite inspections and extensive disclosure requirements and a $794 annual fee. Applicants must provide business and personal contact information, tax identification information, state license details, supplier information, ownership history, security measures and standard operating procedures covering ordering, receiving, inventories, storage, security, dispensing, delivery, distribution, destruction and disposal, theft and loss reporting, due diligence and record keeping.
That is a lot of information to hand to federal regulators. Some of it may be highly sensitive, including supplier relationships, contracts, operating procedures and information about owners and managers. Licensees should consider whether they are comfortable making those disclosures. They should also consider whether any of that information could become subject to Freedom of Information Act requests, or whether competitors or enforcement agencies could eventually see more than the applicant intended.
Disclosure concerns become even more complicated when the application turns to one of the industry’s historic and practical realities: legacy-market history. DEA asks whether the licensee, its suppliers, handlers, officers, partners, shareholders or proprietors have ever been involved in manufacturing, distributing or dispensing unregistered controlled substances. No time limit appears to be stated. For an industry built in part by people who entered cannabis before state-licensed markets existed, that is not an innocent question. Applicants may be forced to choose between disclosing history they would rather not put before federal regulators and omitting information DEA appears to be asking for directly.
The same caution applies to licensees who handle both medical and adult-use marijuana. Registration does not legalize marijuana federally, and adult-use operations remain illegal under federal law, even if licensed by a state. Medical marijuana licensees with recreational activity should think carefully about what they are disclosing and what they may be inviting DEA to inspect.
More broadly, registration may signal the beginning of a more traditional controlled-substances framework for medical cannabis. Schedule III substances typically operate under federal oversight involving FDA-approved products, clinical testing, prescriptions and distribution through licensed health care providers and pharmacies. If medical marijuana is pushed in that direction, today’s registration decision could become the first step into a much more formal federal regulatory regime.
For cannabis businesses, the question is whether the limited safe-harbor benefit and other potential advantages outweigh the disclosure, compliance and enforcement risks. The deadline is short. The implications are significant.
Janet Jackim is a well-seasoned business attorney whose practice focuses on cannabis transactions, litigation, commercial real estate, mergers and acquisitions, and litigation involving the foregoing. She’s been licensed to practice law in Arizona and Colorado for over 45 years. Reach Janet Jackim at jjackim@fennemorelaw.com.
